Explore Products
Tumor Cell Lines

KMM-1

  • BSL

    1

  • 301
Small round-cell morphology, part is multinucleate cell.
Request Your Custom Quote Today

Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.

Get a Quote
  • High Purity Levels
  • Precision and Reliability
  • Customization Options
Product Code

KMM1

Species

Human

Cat.No

ABC-TC0517

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Cell Type

Lymphocyte-like

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Disease

Multiple Myeloma

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Myeloma Cell Lines

Description

KMM-1 is a human plasma cell myeloma cell line that was originally isolated from the malignant subcutaneous tumor of a 62-year-old East Asian patient multiple myeloma. KMM-1 exhibits lymphoblast-like morphology. It displays a small round-cell shape with some multinucleate cells, growing in suspension with noticeable nucleoli and rough endoplasmic reticulum. KMM-1 demonstrated characteristic of plasma cell, it can secrets lambda chain into culture medium and lack expansion of Epstein-Barr virus nuclear antigen. Surface markers include E rosette (-), IgG Fc receptor (-), C3 receptor (-), S-Ig (+), TdT (-), and asialo-GM1 (-). KMM-1 are represent the later stage of B cell differentiation.
View Product Image

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Application

  • KMM-1 cells find diverse applications in research, notably in investigating antioxidant, antiproliferative, and immunostimulatory effects. They serve as a valuable model to study cancer cell apoptosis induction by potential inhibitors. Additionally, they are integral in preclinical trials involving immunophenotypic and immunotypic evaluations. Furthermore, KMM-1 cells hold promise in evaluating potential therapeutic agents, including therapeutic small guide RNAs, against multiple myeloma, contributing significantly to advancing therapeutic strategies in this context.

Inquiring KMM-1

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button